Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells

Leukemia Research

Volumn 28, Issue 11, 2004, Pages 1177-1180

  Joachim Deeg, H ^a,b   Jiang, Peter Y Z ^c   Holmberg, Leona A ^a,b   Scott, Bart ^a,b   Petersdorf, Effie W ^a,b   Appelbaum, Frederick R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Western Washington Medical Group   (United States)

Author keywords

ATG; Etanercept; Flow cytometry; MDS; Transfusion independent

Indexed keywords

ETANERCEPT; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; ERYTHROCYTE; FEMALE; FLOW; FLOW CYTOMETRY; HUMAN; MALE; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PALLIATIVE THERAPY; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; SCORING SYSTEM; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION;

ANTILYMPHOCYTE SERUM; HUMANS; IMMUNOGLOBULIN G; MYELODYSPLASTIC SYNDROMES; PILOT PROJECTS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 4544319588     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.03.016     Document Type: Article

References (15)

1. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., et al. A role for tumor necrosis factor-a. Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br. J. Haematol. 103:1998;176
2. Mundle S.D., Reza S., Ali A., Mativi Y., Shetty V., Venugopal P., et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett. 140:1999;201
3. Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br. J. Haematol. 102:1998;1314
4. Deeg H.J., Gotlib J., Beckham C., Dugan K., Holmberg L., Schubert M., et al. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia. 16:2002;162
5. Reza S., Shetty V., Dar S., Qawi H., Raza A. Tumor necrosis factor-alpha levels decrease with anticytokine therapy in patients with myelodysplastic syndromes. J. Interferon Cytokine Res. 18:1998;871
6. Maciejewski J.P., Risitano A.M., Sloand E.M., Wisch L., Geller N., Barrett J.A., et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome (erratum appears in Br J Haematol June 2002;117(4):1002. Note: Ristiano Antonio M [corrected to Risitano Antonio M]). Br. J. Haematol. 117:2002;119
7. Molldrem J.J., Leifer E., Bahceci E., Saunthararajah Y., Rivera M., Dunbar C., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndrome [summary for patients in Ann Intern Med 6 August 2002;137(3):1-27]. Ann. Intern. Med. 137:2002;156
8. Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood. 101:2003;2156
9. Killick S.B., Mufti G., Cavenagh J.D., Mijovic A., Peacock J.L., Gordon-Smith E.C., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br. J. Haematol. 120:2003;679
10. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisenring W.M., et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood. 102:2003;394
11. Doney K., Leisenring W., Storb R., Appelbaum F.R. For the Seattle Bone Marrow Transplant Team. Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Ann. Intern. Med. 126:1997;107
12. Cheson B.D., Bennett J.M., Kantarjian H., Pinto A., Schiffer C.A., Nimer S.D., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 96:2000;3671
13. Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 100:2002;1570
14. Okamoto T. Relationship between response to cyclosporine treatment and HLA-DR in MDS [Japanese]. Rinsho Ketsueki - Japanese J Clin. Hematol. 43:2002;265
15. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood. 102:2003;3025